Summary
We have studied the tolerability and plasma drug profiles of a leukotriene D4 receptor antagonist, MK-571, given intravenously and as an oral solution in two separate trials.
Study I (i.v.) involved 2 panels of 6 healthy men in a double-blind, alternating, incrementally increasing dose study with single doses up to 1500 mg. There was good tolerability at all doses. Plasma was assayed stereospecifically by HPLC for the S(+) and R(−) enantiomers of MK-571. For each enantiomer AUC values increased more than proportionately with increasing dose, suggesting nonlinear kinetics. The S(+) enantiomer was cleared more rapidly than the R(−) enantiomer. The apparent initial volume of distribution was less than 101 for both enantiomers.
Study II (oral) involved 18 healthy subjects in 3 parallel groups who took multiple oral doses of 100, 300, and 600 mg t. i. d. for 31 doses. MK-571 administration was well tolerated, with only mild to moderate gastrointestinal discomfort at the highest dose. Total MK-571 (plasma samples assayed nonstereoselectively) was rapidly absorbed after oral administration, reaching peak concentrations at 1–2 h. Mean 8 h AUC increased from dose 1 to dose 31 in all subjects at all doses, suggesting a modest extent of accumulation (about 50 %) of total MK-571 in plasma with a t. i. d. dosage regimen.
Similar content being viewed by others
References
Adelroth E, Morris MM, Hargreave FE, O'Byrne PM (1986) Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. New Engl J Med 315: 480–484
Dahlèn SE, Hedqvist P, Hammarström S, Samuelsson B (1980) Leukotrienes are potent constrictors of human bronchi. Nature 288: 484–486
Hendeles L, Davison D, Blake K, Harman E, Cooper R, Margolskee D (1990) Leukotriene D4 is an important mediator of antigen-induced bronchoconstriction: attenuation of dual response with MK-571, a specific LTD4 receptor antagonist. J Allergy Clin Immunol 85: 197 (Abstract)
Jones TR, Zamboni R, Belley M, Champion E, Charette L, Ford-Hutchinson AW, Frenette R, Gauthier JY, Leger S, Masson P, McFarlane CS, Piechuta H, Rokach J, Williams H, Young RN (1989) Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol 67: 17–28
Kips JC, Joos GF, De Lepeleire I, Margolskee DJ, Buntinx A, Pauwels RA, Van Der Straeten ME (1991) MK-571: a potent antagonist of leukotriene D4-induced bronchoconstriction in the human. Am Rev Respir Dis 144: 617–621
Marom Z, Shelhamer JH, Bach MK, Morton DR, Kaliner M (1982) Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airwaysin vitro. Am Rev Respir Dis 126: 449–451
Rasmussen JB, Margolskee DJ, Eriksson LO, Williams VC, Andersson KE (1991) Leukotriene (LT)D4 is involved in antigen-induced asthma: a study with the LTD4 receptor antagonist, MK-571. Ann NY Acad Sci 629: 436
Robinett R, Hsieh JY-K (1991) Stereoselective determination of R(−) and S(+) MK-571 in human plasma by chiral high performance liquid chromatography. J Chromatogr Biomed Appl 570: 157–165
Smith LJ, Greenberger PA, Patterson R, Krell RO, Bernstein PR (1985) The effect of inhaled leukotriene D4 in humans. Am Rev Respir Dis 131: 449–451
Soter NA, Lewis RA, Corey EJ, Austen KF (1983) Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4 and LTB4) in human skin. J Invest Dermatol 80: 115–119
Tocco DJ, de Luna FA, Duncan AEW, Hsieh JH, Lin JH (1990) Interspecies differences in Stereoselective protein binding and clearance of MK-571. Drug Metab Dispos 18: 388–392
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Depré, M., Margolskee, D.J., Hsieh, J.Y.K. et al. Plasma drug profiles and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in man. Eur J Clin Pharmacol 43, 427–430 (1992). https://doi.org/10.1007/BF02220621
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02220621